Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

An in vitro investigation of the cardiovascular effects of the 5-HT(4) receptor selective agonists, velusetrag and TD-8954.

Beattie DT, Higgins DL, Ero MP, Amagasu SM, Vickery RG, Kersey K, Hopkins A, Smith JA.

Vascul Pharmacol. 2013 Jan;58(1-2):150-6. doi: 10.1016/j.vph.2012.11.002. Epub 2012 Nov 29.

PMID:
23201772
2.

The inability of tegaserod to affect platelet aggregation and coronary artery tone at supratherapeutic concentrations.

Higgins DL, Ero MP, Loeb M, Kersey K, Hopkins A, Beattie DT.

Naunyn Schmiedebergs Arch Pharmacol. 2012 Jan;385(1):103-9. doi: 10.1007/s00210-011-0687-x. Epub 2011 Sep 8.

PMID:
21901313
3.

Effects of telavancin on coagulation test results.

Barriere SL, Goldberg MR, Janc JW, Higgins DL, Macy PA, Adcock DM.

Int J Clin Pract. 2011 Jul;65(7):784-9. doi: 10.1111/j.1742-1241.2011.02668.x. Epub 2011 May 13.

PMID:
21564449
4.

Bibliotherapy as a treatment for depression in primary care.

Naylor EV, Antonuccio DO, Litt M, Johnson GE, Spogen DR, Williams R, McCarthy C, Lu MM, Fiore DC, Higgins DL.

J Clin Psychol Med Settings. 2010 Sep;17(3):258-71. doi: 10.1007/s10880-010-9207-2.

PMID:
20803165
5.

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.

Higgins DL, Chang R, Debabov DV, Leung J, Wu T, Krause KM, Sandvik E, Hubbard JM, Kaniga K, Schmidt DE Jr, Gao Q, Cass RT, Karr DE, Benton BM, Humphrey PP.

Antimicrob Agents Chemother. 2005 Mar;49(3):1127-34.

6.

Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects.

Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S.

Antimicrob Agents Chemother. 2005 Jan;49(1):195-201.

7.

Chlamydia pneumoniae and coronary artery disease: legitimized linkages?

Higgins JP, Higgins JA, Higgins PM, Ahuja S, Higgins DL.

Expert Rev Cardiovasc Ther. 2003 Sep;1(3):367-84. Review.

PMID:
15030265
8.

In vitro activity of TD-6424 against Staphylococcus aureus.

Pace JL, Krause K, Johnston D, Debabov D, Wu T, Farrington L, Lane C, Higgins DL, Christensen B, Judice JK, Kaniga K.

Antimicrob Agents Chemother. 2003 Nov;47(11):3602-4.

9.

Multivalent drug design. Synthesis and in vitro analysis of an array of vancomycin dimers.

Griffin JH, Linsell MS, Nodwell MB, Chen Q, Pace JL, Quast KL, Krause KM, Farrington L, Wu TX, Higgins DL, Jenkins TE, Christensen BG, Judice JK.

J Am Chem Soc. 2003 May 28;125(21):6517-31.

PMID:
12785792
10.

Addressing urban health in Detroit, New York City, and Seattle through community-based participatory research partnerships.

Metzler MM, Higgins DL, Beeker CG, Freudenberg N, Lantz PM, Senturia KD, Eisinger AA, Viruell-Fuentes EA, Gheisar B, Palermo AG, Softley D.

Am J Public Health. 2003 May;93(5):803-11.

11.

Housing and health: time again for public health action.

Krieger J, Higgins DL.

Am J Public Health. 2002 May;92(5):758-68. Review.

12.

Implementing community-based participatory research centers in diverse urban settings.

Higgins DL, Metzler M.

J Urban Health. 2001 Sep;78(3):488-94. Review. No abstract available.

13.

CDC Urban Research Centers: community-based participatory research to improve the health of urban communities.

Higgins DL, Maciak B, Metzler M; CDC Urban Research Centers.

J Womens Health Gend Based Med. 2001 Jan-Feb;10(1):9-15. No abstract available.

PMID:
11224940
14.

Protein affinity map of chemical space.

Kauvar LM, Villar HO, Sportsman JR, Higgins DL, Schmidt DE Jr.

J Chromatogr B Biomed Sci Appl. 1998 Sep 11;715(1):93-102.

PMID:
9792501
15.

The effects of HIV counseling and testing on risk-related practices and help-seeking behavior.

Wolitski RJ, MacGowan RJ, Higgins DL, Jorgensen CM.

AIDS Educ Prev. 1997 Jun;9(3 Suppl):52-67. Review.

PMID:
9241398
16.

Ligand-based protein alignment and isozyme specificity of glutathione S-transferase inhibitors.

Koehler RT, Villar HO, Bauer KE, Higgins DL.

Proteins. 1997 Jun;28(2):202-16.

PMID:
9188738
17.

Glubodies: randomized libraries of glutathione transferase enzymes.

Napolitano EW, Villar HO, Kauvar LM, Higgins DL, Roberts D, Mandac J, Lee SK, Engqvist-Goldstein A, Bukar R, Calio BL, Jäck HM, Tainer JA.

Chem Biol. 1996 May;3(5):359-67.

18.

Increasing the use of bleach and condoms among injecting drug users in Denver: outcomes of a targeted, community-level HIV prevention program.

Rietmeijer CA, Kane MS, Simons PZ, Corby NH, Wolitski RJ, Higgins DL, Judson FN, Cohn DL.

AIDS. 1996 Mar;10(3):291-8.

PMID:
8882669
19.

Building a peer network for a community level HIV prevention program among injecting drug users in Denver.

Simons PZ, Rietmeijer CA, Kane MS, Guenther-Grey C, Higgins DL, Cohn DL.

Public Health Rep. 1996;111 Suppl 1:50-3.

20.

Using formative research to lay the foundation for community level HIV prevention efforts: an example from the AIDS Community Demonstration Projects.

Higgins DL, O'Reilly K, Tashima N, Crain C, Beeker C, Goldbaum G, Elifson CS, Galavotti C, Guenther-Grey C.

Public Health Rep. 1996;111 Suppl 1:28-35.

21.

Predicting ligand binding to proteins by affinity fingerprinting.

Kauvar LM, Higgins DL, Villar HO, Sportsman JR, Engqvist-Goldstein A, Bukar R, Bauer KE, Dilley H, Rocke DM.

Chem Biol. 1995 Feb;2(2):107-18.

23.

Men's disclosure of HIV test results to male primary sex partners.

Schnell DJ, Higgins DL, Wilson RM, Goldbaum G, Cohn DL, Wolitski RJ.

Am J Public Health. 1992 Dec;82(12):1675-6.

24.
25.

Conformational similarities between one-chain and two-chain tissue plasminogen activator (t-PA): implications to the activation mechanism on one-chain t-PA.

Nienaber VL, Young SL, Birktoft JJ, Higgins DL, Berliner LJ.

Biochemistry. 1992 Apr 21;31(15):3852-61.

PMID:
1314651
26.
27.

Evidence for the effects of HIV antibody counseling and testing on risk behaviors.

Higgins DL, Galavotti C, O'Reilly KR, Schnell DJ, Moore M, Rugg DL, Johnson R.

JAMA. 1991 Nov 6;266(17):2419-29. Review.

PMID:
1920748
28.

AIDS Community Demonstration Projects for HIV prevention among hard-to-reach groups.

O'Reilly KR, Higgins DL.

Public Health Rep. 1991 Nov-Dec;106(6):714-20.

29.

Inhibition of glycogen synthesis in Saccharomyces cerevisiae by the mating pheromone alpha-factor.

François J, Higgins DL, Chang F, Tatchell K.

J Biol Chem. 1991 Apr 5;266(10):6174-80.

30.

Plasminogen activator activities of equimolar complexes of streptokinase with variant recombinant plasminogens.

Davidson DJ, Higgins DL, Castellino FJ.

Biochemistry. 1990 Apr 10;29(14):3585-90.

PMID:
2141279
31.

The effect of the one-chain to two-chain conversion in tissue plasminogen activator: characterization of mutations at position 275.

Higgins DL, Lamb MC, Young SL, Powers DB, Anderson S.

Thromb Res. 1990 Feb 15;57(4):527-39.

PMID:
2139248
32.

Tissue plasminogen activator: the biochemistry and pharmacology of variants produced by mutagenesis.

Higgins DL, Bennett WF.

Annu Rev Pharmacol Toxicol. 1990;30:91-121. Review. No abstract available.

PMID:
2111656
33.

Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.

Schleef RR, Higgins DL, Pillemer E, Levitt LJ.

J Clin Invest. 1989 May;83(5):1747-52.

35.

Human fibrinogen.

Shafer JA, Higgins DL.

Crit Rev Clin Lab Sci. 1988;26(1):1-41. Review.

PMID:
3286116
36.
37.

Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis.

Tate KM, Higgins DL, Holmes WE, Winkler ME, Heyneker HL, Vehar GA.

Biochemistry. 1987 Jan 27;26(2):338-43.

PMID:
3103680
38.
39.

Lipid mobility in the assembly and expression of the activity of the prothrombinase complex.

Higgins DL, Callahan PJ, Prendergast FG, Nesheim ME, Mann KG.

J Biol Chem. 1985 Mar 25;260(6):3604-12.

40.

Steady state kinetic parameters for the thrombin-catalyzed conversion of human fibrinogen to fibrin.

Higgins DL, Lewis SD, Shafer JA.

J Biol Chem. 1983 Aug 10;258(15):9276-82.

41.
42.
44.

Fibrinogen Petoskey: identification of a new dysfibrinogenemia characterized by altered release of fibrinopeptide A.

Higgins DL, Penner JA, Shafer JA.

Thromb Res. 1981 Sep 15;23(6):491-504. No abstract available.

45.

An immobilized naphthylamide substrate for proteinases with tryptic-like specificity.

Higgins DL, Shafer JA.

Anal Biochem. 1977 Dec;83(2):408-15. No abstract available.

Supplemental Content

Loading ...
Support Center